High-Dose Influenza Vaccine with Evidence of Superior Efficacy* in Older Adults: Now in Canada

¹ Public Health Agency of Canada (2016). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older.

² Product Monograph: FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Split Virion). Sanofi Pasteur.  Approved May 2016

³ Public Health Agency of Canada (2016). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017.

⁴ DiazGranados, C.A. et al. (2014). Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England Journal of Medicine 371, 635-645.

⁵ Centers of Disease Control and Prevention. People at High Risk of Developing Flu Related Complications. http://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed September 2016.

⁶ Udell J.A., et al. (2015). Does influenza vaccination influence cardiovascular complications? Expert Rev Cardiovasc Ther. 13:593-596.

*Against lab-confirmed influenza illness compared to a standard dose influenza vaccine

^† FLUZONE^® Influenza Virus Vaccine Trivalent Types A and B (Split Virion)

‡ FLUZONE^® High-Dose Influenza Vaccine is not indicated to treat or prevent heart attacks or stroke.